Cointime

ROME Therapeutics

company

About

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome.

  • 1 - 10

Highlights

Total Funding Amount
$127M
Funding Rounds
2
Investors
1
Investments
1

Details

Last Funding Type
Series A
Last Funding Money Raised
$50M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2020
Number Of Employee
1 - 10
Operating Status
Active

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$127M
ROME Therapeutics has raised a total of $127M in funding over 2 rounds. Their latest funding was raised on Sep 14, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 14, 2021 Series B $77M 1 — — Detail
Apr 27, 2020 Series A $50M 1 — — Detail

Investments

Number of Investments
Number of Lead Investments
1
0
ROME Therapeutics has made 1 investments. Their most recent investment was on Aug 11, 2017, when Sleeper raised $2M.
Date Company Name
Round Money Raised Industry Lead Investor
Aug 11, 2017 Sleeper
Seed $2M eSports —

Investors

Number of Lead Investors
Number of Investors
—
1
ROME Therapeutics is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners — Series B
Cointime
Content
Company